Hp1-1 as a Genetic Marker Regulating Inflammation and the Possibility of Developing Diabetic Complications in Patients with Type 2 Diabetes-Cohort Studies.
Adult
Aged
Antigens, CD
/ blood
Antigens, Differentiation, Myelomonocytic
/ blood
Cardiovascular Diseases
/ blood
Case-Control Studies
Diabetes Complications
/ genetics
Diabetes Mellitus, Type 2
/ complications
Female
Genetic Markers
/ genetics
HMGB1 Protein
/ blood
Haptoglobins
/ genetics
Humans
Inflammation
/ blood
Interleukin-10
/ blood
Male
Middle Aged
Protein Isoforms
/ genetics
Receptors, Cell Surface
/ blood
Risk Factors
Tumor Suppressor Protein p53
/ blood
cardiovascular disease
haptoglobin phenotypes
inflammatory markers
type 2 diabetes
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
24 10 2020
24 10 2020
Historique:
received:
24
09
2020
revised:
12
10
2020
accepted:
21
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
24
7
2021
Statut:
epublish
Résumé
This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes. The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease. Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease. Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body's inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes.
Sections du résumé
BACKGROUND
This study assessed the influence of the haptoglobin phenotype on markers regulating inflammation in patients with type 2 diabetes.
METHODS
The haptoglobin phenotypes, soluble form of CD163 receptor (sCD163), p53 concentrations and high mobility group box protein 1 (HMGB1), interleukin 10 (IL-10) secretion in serum were assayed via ELISA tests. In the first part of the project, patients were divided into three groups which differed by the haptoglobin phenotype, and afterwards into two groups according to the criterion of the presence or absence of cardiovascular disease.
RESULTS
Diabetic patients with haptoglobin phenotype 1-1 (Hp1-1) had a significantly higher concentration of IL-10 and sCD163 compared to haptoglobin phenotype 2-1 (Hp2-1) and haptoglobin phenotype 2-2 (Hp2-2). Moreover, diabetic patients with Hp1-1 had a significantly lower concentration of p53 and HMGB1 compared to diabetic patients with Hp2-1 and Hp2-2. The results have shown that diabetics with Hp2-1 had a significantly lower postprandial glucose level compared to diabetics with Hp2-2. Apart from that, there were no differences in the occurrence of haptoglobin variants between patients with or without cardiovascular disease.
CONCLUSIONS
Our study provides new data for a relationship between the type of haptoglobin in patients with type 2 diabetes and the concentration of factors that regulate the body's inflammation. We have shown that the Hp1-1 can serve as a genetic marker of inflammatory processes.
Identifiants
pubmed: 33114431
pii: genes11111253
doi: 10.3390/genes11111253
pmc: PMC7716206
pii:
doi:
Substances chimiques
Antigens, CD
0
Antigens, Differentiation, Myelomonocytic
0
CD163 antigen
0
Genetic Markers
0
HMGB1 Protein
0
HMGB1 protein, human
0
HP protein, human
0
Haptoglobins
0
IL10 protein, human
0
Protein Isoforms
0
Receptors, Cell Surface
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Interleukin-10
130068-27-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
All authors declare no potential conflict of interest.
Références
Rev Esp Cardiol. 2002 Jul;55(7):738-50
pubmed: 12113702
Front Cardiovasc Med. 2018 Oct 16;5:141
pubmed: 30386783
Arterioscler Thromb Vasc Biol. 2011 Feb;31(2):313-9
pubmed: 21088249
J Clin Invest. 1995 Nov;96(5):2304-10
pubmed: 7593617
Diabetes Care. 2010 Apr;33(4):861-8
pubmed: 20067962
Clin Chem. 1996 Oct;42(10):1589-600
pubmed: 8855140
Oncotarget. 2014 Jul 30;5(14):5535-46
pubmed: 25114038
Clin Diabetes. 2016 Jul;34(3):148-57
pubmed: 27621532
Nat Commun. 2013;4:2935
pubmed: 24343302
Cold Spring Harb Perspect Med. 2016 Mar 01;6(3):a026104
pubmed: 26931810
J Cardiovasc Transl Res. 2012 Aug;5(4):423-35
pubmed: 22447230
Autoimmun Rev. 2012 Oct;11(12):909-17
pubmed: 22495229
Biofactors. 2017 May 6;43(3):424-433
pubmed: 28218436
Clin Exp Immunol. 2002 Oct;130(1):156-61
pubmed: 12296867
Diabetes. 2010 Jan;59(1):135-42
pubmed: 19833883
Circ Res. 2013 Mar 15;112(6):911-23
pubmed: 23381569
Blood. 2002 Jan 1;99(1):378-80
pubmed: 11756196
J Am Heart Assoc. 2014 May 16;3(3):e000732
pubmed: 24837587
Cell Rep. 2016 Mar 15;14(10):2413-25
pubmed: 26947067
Cardiovasc Diabetol. 2018 Jan 16;17(1):14
pubmed: 29338727
Eur Respir J. 2017 Aug 17;50(2):
pubmed: 28818879
Mol Med. 2015 Oct 27;21 Suppl 1:S6-S12
pubmed: 26605648
Atherosclerosis. 2012 Apr;221(2):317-8
pubmed: 22204863
Cytometry B Clin Cytom. 2005 Jan;63(1):16-22
pubmed: 15624200
Int J Mol Sci. 2018 Mar 08;19(3):
pubmed: 29518025
J Am Coll Cardiol. 2013 Feb 19;61(7):728-37
pubmed: 23312704
Exp Clin Endocrinol Diabetes. 2012 May;120(5):277-81
pubmed: 22549347
Crit Rev Immunol. 2012;32(1):23-63
pubmed: 22428854
Circ Res. 2007 Jul 6;101(1):106-10
pubmed: 17525367
Atherosclerosis. 2007 Mar;191(1):48-53
pubmed: 16820150
J Leukoc Biol. 2000 Jan;67(1):97-103
pubmed: 10648003
Crit Care Med. 2008 Aug;36(8):2407-13
pubmed: 18596634
Inflamm Allergy Drug Targets. 2010 Mar;9(1):60-72
pubmed: 19906009
Phytomedicine. 2017 Aug 15;32:68-73
pubmed: 28732809
Annu Rev Physiol. 2017 Feb 10;79:541-566
pubmed: 27813830
J Endocrinol. 2016 Nov;231(2):R61-R75
pubmed: 27613337
Cardiovasc Res. 2004 Sep 1;63(4):582-92
pubmed: 15306213
J Leukoc Biol. 2005 Jul;78(1):1-8
pubmed: 15734795
J Am Coll Cardiol. 2002 Dec 4;40(11):1984-90
pubmed: 12475459
Immunobiology. 2005;210(2-4):153-60
pubmed: 16164022
Arterioscler Thromb Vasc Biol. 2020 Jan;40(1):20-33
pubmed: 31722535
Cytobios. 2000;101(398):145-50
pubmed: 10755213
Int J Clin Exp Pathol. 2018 May 01;11(5):2401-2407
pubmed: 31938352
J Leukoc Biol. 2004 Jul;76(1):271-7
pubmed: 15075364
Circ Res. 2004 Jan 9;94(1):119-26
pubmed: 14656926
Cardiovasc Diabetol. 2019 May 30;18(1):65
pubmed: 31146758
Clin Biochem. 2009 Nov;42(16-17):1662-6
pubmed: 19596303
Mol Biol (Mosk). 2007 Nov-Dec;41(6):989-93
pubmed: 18318116
Exp Ther Med. 2017 Sep;14(3):2431-2433
pubmed: 28962177
Clin Chem Lab Med. 2013 Aug;51(8):1615-22
pubmed: 23492570
Genet Test Mol Biomarkers. 2012 Jun;16(6):563-8
pubmed: 22300541
Atherosclerosis. 2006 Feb;184(2):342-7
pubmed: 15979079
Phytomedicine. 2015 Dec 15;22(14):1255-61
pubmed: 26655408
Angiology. 2018 Sep;69(8):730-735
pubmed: 29482350
J Diabetes Res. 2016;2016:2543268
pubmed: 28101517
Circ Res. 1999 Oct 15;85(8):e17-24
pubmed: 10521249